Stock Markets February 5, 2026

JPMorgan Lowers Corteva to Neutral, Cites Valuation Constraints

Bank applies sum-of-the-parts valuation as investors await clarity on crop risks and the planned corporate split

By Avery Klein CTVA
JPMorgan Lowers Corteva to Neutral, Cites Valuation Constraints
CTVA

JPMorgan has downgraded Corteva from Overweight to Neutral, arguing the stock's current price already reflects much of the upside and that valuation levers are limited until agricultural risks and the planned separation of the seed and crop protection businesses become clearer. The bank adjusted its price target slightly higher after lifting consolidated EBITDA forecasts, but trimmed 2026 EPS on expected higher financing costs and currency losses.

Key Points

  • JPMorgan downgraded Corteva to Neutral from Overweight, citing valuation constraints; shares were down 1.3% at $74.
  • The bank values Corteva using a sum-of-the-parts approach - 13.5x for the seed business and 10x for crop protection - and says each multiple point on Seed equals about $4.50/share.
  • JPMorgan raised its price target to $77 from $75 after increasing its consolidated EBITDA forecast to $4.2 billion, but trimmed 2026 EPS to $3.70 from $3.80 due to higher net interest expense and currency losses.

JPMorgan has reduced its rating on Corteva to Neutral from Overweight, pointing to valuation concerns even as it nudged its price target slightly higher. The stock was trading down 1.3% at $74 at the time of the bank's action.

The bank used a sum-of-the-parts framework to value Corteva's businesses, applying a 13.5x multiple to the seed division and a 10x multiple to the crop protection unit. JPMorgan noted that investors who take a more bullish view might assign a higher multiple to the Seed business, but cautioned that market participants may be reluctant to settle on a precise multiple until the risks tied to the current crop year are clearer and the planned spin separation is imminent.

Analysts at JPMorgan elaborated on the sensitivity of valuation assumptions, stating: "More optimistic investors may believe that the Seed business should carry a higher multiple than we have placed on the business. We think that each multiple point turn on the Seed operation is worth about $4.50/share." The bank also observed that Monsanto historically traded around 13x EBITDA, with a typical range of 10x to 14x.

At the same time, JPMorgan highlighted factors that could constrain any further rerating. The firm pointed to nearly 99 million acres of corn planted in 2025, which it said could signal a cyclically strong period for the company. Given that backdrop, the bank suggested investors may prefer to await greater clarity on crop-related risks and on the timing and mechanics of Corteva's planned separation of its seed and crop chemical businesses before assigning higher valuations to the shares.

Despite the downgrade, JPMorgan raised its price target to $77 from $75 after increasing its consolidated EBITDA estimate to $4.2 billion from $4.15 billion. The bank cited expectations for stronger operating profits from the seed business as the reason for the EBITDA upgrade, but concluded that the shares look fairly valued at current levels.

Corteva has announced plans to split into two companies in the second half of 2026, most likely in the fourth quarter, a development that JPMorgan said markets may want to see progress on before re-rating the stock.

The bank also trimmed its 2026 earnings-per-share forecast to $3.70 from $3.80, attributing the reduction to higher net interest expenses and larger currency-related losses.

In its commentary, JPMorgan summed up the rationale plainly: "We downgrade Corteva shares to Neutral based on valuation. The company is trading near our previous December 2026 price target of $75."

Separately, a portfolio research product mentioned in relation to the stock evaluates Corteva alongside thousands of other companies each month using more than 100 financial metrics. That product notes it identifies ideas based on fundamentals, momentum and valuation, and cites past winners including Super Micro Computer (+185%) and AppLovin (+157%).


What this means

  • The rating change reflects JPMorgan's view that upside from valuation multiple expansion is limited at current prices.
  • Near-term company prospects are being weighed against crop-year risks and the upcoming corporate separation.
  • Analysts adjusted operating forecasts upward for EBITDA but reduced 2026 EPS due to financing and currency pressures.

Risks

  • Crop-year uncertainty - Investors may delay re-rating the stock until crop risks are clearer, which affects agricultural and agribusiness sectors.
  • Corporate separation timing - The planned split of seed and crop chemical businesses in H2 2026 (likely Q4) introduces execution and timing uncertainty for the agribusiness sector.
  • Financial headwinds - Higher net interest expense and increased currency-related losses could weigh on 2026 earnings, impacting investor sentiment in agriculture-related equities.

More from Stock Markets

Wolfe Identifies Business and Information Services Picks Set to Benefit from 2026 Market Tailwinds Feb 5, 2026 Warsaw Stocks Slide as WIG30 Drops 2.37%; Basic Materials, Oil & Gas and Banks Lead Losses Feb 5, 2026 Copenhagen Shares Slide; OMX Copenhagen 20 Drops to One-Month Low Feb 5, 2026 Benchmark Starts Coverage of CAVA With Buy Rating, $80 Price Target Feb 5, 2026 BTIG Identifies 10 Healthcare Stocks It Expects to Outperform in 2026 Feb 5, 2026